The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with  Intracytoplasmic Sperm Injection Outcomes in Iraqi Infertile men

The Relation of Seminal Cell-Free DNA and Total... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/14-719" }, "headline": "The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with Intracytoplasmic Sperm...", "datePublished": "2025-07-22T15:02:35", "dateModified": "2025-07-22T15:02:35", "author": [ { "@type": "Person", "name": "Hadeer S. Al- Shammary" }, { "@type": "Person", "name": "Hanan L. Al-Omary" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": " Background Oxidative stress has increasingly been implicated as a factor in male infertility and poorer outcomes from assisted reproduction procedures. This study aims to evaluate the relationship between seminal cell-free DNA (cfDNA) levels and total antioxidant capacity (TAC), and the results of ICSI. Methods Sixty-five couples undergoing ICSI were enrolled in the study, including 45 men with a sperm abnormality and 20 with normal sperm parameters. Seminal cfDNA and TAC levels were measured and correlated with semen quality metrics and ICSI outcomes such as fertilization rates, embryo quality grades, pregnancy achievement, and miscarriage rates. Results Men with abnormal sperm parameters showed significantly elevated cfDNA levels (3.482 ± 0.936 μg/ml) and reduced TAC (1260.42 ± 251.29 μM/ml) compared to their counterparts with normospermia (cfDNA: 0.631 ± 0.454 μg/ml; TAC: 1847.80 ± 70.71 μM/ml; p = 0.0001). cfDNA increased and TAC decreased with increasing severity of sperm abnormalities. cfDNA correlated negatively with progressive motility and morphology but positively with numbers of non-motile sperms. High cfDNA linked to poorer embryo quality grades, lower pregnancy rates, and increased chance of miscarriage. In contrast, higher TAC correlated positively with sperm motility and morphology and was considerably higher in cases achieving pregnancy as well as those with lower miscarriage risk, indicating its value in forecasting favorable ICSI outcomes. Conclusion Seminal cfDNA and TAC serve as reliable, non-invasive biomarkers of sperm oxidative damage and show promise in anticipating ICSI achievement. Their clinical application may enhance diagnostic precision and therapeutic decision making in male infertility management. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/14-719/v1", "name": "The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity..." } } ] } Home Browse The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article S. Al- Shammary H and L. Al-Omary H. The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with Intracytoplasmic Sperm Injection Outcomes in Iraqi Infertile men [version 1; peer review: 1 approved] . F1000Research 2025, 14 :719 ( https://doi.org/10.12688/f1000research.166880.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with Intracytoplasmic Sperm Injection Outcomes in Iraqi Infertile men [version 1; peer review: 1 approved] Hadeer S. Al- Shammary https://orcid.org/0009-0003-3136-4747 1 , Hanan L. Al-Omary https://orcid.org/0000-0001-5686-6178 1 Hadeer S. Al- Shammary https://orcid.org/0009-0003-3136-4747 1 , Hanan L. Al-Omary https://orcid.org/0000-0001-5686-6178 1 PUBLISHED 22 Jul 2025 Author details Author details 1 Department of Physiology, University of Baghdad, College of Medicine, Baghdad, 10011, Iraq Hadeer S. Al- Shammary Roles: Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Writing – Original Draft Preparation Hanan L. Al-Omary Roles: Conceptualization, Methodology, Supervision, Validation, Visualization, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Background Oxidative stress has increasingly been implicated as a factor in male infertility and poorer outcomes from assisted reproduction procedures. This study aims to evaluate the relationship between seminal cell-free DNA (cfDNA) levels and total antioxidant capacity (TAC), and the results of ICSI. Methods Sixty-five couples undergoing ICSI were enrolled in the study, including 45 men with a sperm abnormality and 20 with normal sperm parameters. Seminal cfDNA and TAC levels were measured and correlated with semen quality metrics and ICSI outcomes such as fertilization rates, embryo quality grades, pregnancy achievement, and miscarriage rates. Results Men with abnormal sperm parameters showed significantly elevated cfDNA levels (3.482 ± 0.936 μg/ml) and reduced TAC (1260.42 ± 251.29 μM/ml) compared to their counterparts with normospermia (cfDNA: 0.631 ± 0.454 μg/ml; TAC: 1847.80 ± 70.71 μM/ml; p = 0.0001). cfDNA increased and TAC decreased with increasing severity of sperm abnormalities. cfDNA correlated negatively with progressive motility and morphology but positively with numbers of non-motile sperms. High cfDNA linked to poorer embryo quality grades, lower pregnancy rates, and increased chance of miscarriage. In contrast, higher TAC correlated positively with sperm motility and morphology and was considerably higher in cases achieving pregnancy as well as those with lower miscarriage risk, indicating its value in forecasting favorable ICSI outcomes. Conclusion Seminal cfDNA and TAC serve as reliable, non-invasive biomarkers of sperm oxidative damage and show promise in anticipating ICSI achievement. Their clinical application may enhance diagnostic precision and therapeutic decision making in male infertility management. READ ALL READ LESS Keywords Cell-free DNA, Total Antioxidant Capacity, Oxidative stress, Intracytoplasmic sperm injection, Sperm DNA fragmentation Corresponding Author(s) Hadeer S. Al- Shammary ( [email protected] ) Close Corresponding author: Hadeer S. Al- Shammary Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2025 S. Al- Shammary H and L. Al-Omary H. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: S. Al- Shammary H and L. Al-Omary H. The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with Intracytoplasmic Sperm Injection Outcomes in Iraqi Infertile men [version 1; peer review: 1 approved] . F1000Research 2025, 14 :719 ( https://doi.org/10.12688/f1000research.166880.1 ) First published: 22 Jul 2025, 14 :719 ( https://doi.org/10.12688/f1000research.166880.1 ) Latest published: 22 Jul 2025, 14 :719 ( https://doi.org/10.12688/f1000research.166880.1 ) Introduction Infertility is a significant global health problem, with male factors contributing to approximately 50% of all cases. 1 Despite that several causes, including hormonal abnormalities, genetic diseases, infection, and exposure to environmental pollutants have been identified, many of cases are still idiopathic, even if the patient has normal semen parameters. 2 Classic semen analysis assesses concentration, motility, and morphology, but these parameters do not always reflect the functional and molecular competence of spermatozoa. 3 Among the ART procedures, ICSI has been one of the most commonly used techniques for the treatment of male factor infertility especially when routine semen characteristics are severely deranged. Although ICSI bypass many physiological barriers to fertilization, it cannot correct pre-existing DNA damage due to oxidative stress (OS). It is shown that sperm with highly fragmented DNA could have normal morphology and motility. 4 , 5 In this regard, conventional selection criteria does not exclude the injection of a spermatozoon with high DNA damage. This limitation underscores the need for molecular-level indicators to enhance ICSI outcome prediction. OS is among the most studied factors associated with male infertility. 6 , 7 Excess production of reactive oxygen species (ROS) or inefficient scavenging may lead to lipid, protein, and DNA damage, affecting sperm viability and function. 8 , 9 In high concentrations, ROS negatively impact sperm capacitation and fertilization by causing mitochondrial injury, membrane instability, and DNA damage of the male gamete. 10 Seminal plasma creates a protective and antioxidant milieu which is crucial to protect sperm function. 11 , 12 Seminal total antioxidant capacity (TAC) reflects the overall activity of all antioxidants within seminal fluid and is used as an OS status marker. TAC has found to be substantially lower in infertile men, 13 particularly in oligoasthenoteratozoospermic (OAT) men, as compared to fertile individuals. 14 Seminal plasma cell-free DNA (cfDNA) has recently been proposed as a promising biomarker. This DNA consists of extracellular DNA fragments that are present in seminal plasma through several means, apoptosis, necrosis, active cellular excretion, and neutrophil extracellular trap formation (NETosis). 15 , 16 The existence of cfDNA in semen was first demonstrated in 2004 by Chou and coworkers, who described it as being of two major types: low molecular weight (1 kb) DNA and high molecular weight (~12 kb) DNA. 17 Later studies showed that cfDNA from seminal plasma is of a wide range size (180 bps to 15 kb) indicating various types of cellular origin and release methods. 18 , 19 Seminal cfDNA has been associated with reduced sperm quality and higher DNA fragmentation. 20 , 21 As a non-cellular biomarker, cfDNA could offer a non-invasive means to evaluate sperm genome integrity and complements traditional semen parameters in fertility assessment. While OS markers like TAC and cfDNA have been correlated with sperm dysfunction, their influence on ICSI outcomes remain inadequately explored. Although pregnancy rates represent the primary measure of ART success in several studies, the utility of miscarriage rates may be more revealing. As ICSI bypasses natural selection processes that occurs during normal fertilization, even DNA-damaged sperm may fertilise an oocyte. 22 – 24 Hence, assessing miscarriage rates offers an appropriate estimation of post-fertilization embryo viability and the effects of oxidative DNA damage. This study aimed to assess the levels of cfDNA and TAC in the seminal plasma of males undergoing ICSI. It is also sought to evaluate the correlation between these markers and ICSI outcomes including embryo grading, fertilization rate, pregnancy rate, and miscarriage rate, and to investigate their relationship with conventional semen parameters such as sperm concentration, motility, and morphology. Methods Declaration of ethical principles The study was conducted in accordance with the guidelines of the Ethics Committee of the College of Medicine, University of Baghdad, under approval number 292, dated December 24, 2023. Written informed consent was obtained from all participating couples prior to their inclusion in the study. Study design This is a cross-sectional study conducted at the High Institute for Infertility Diagnosis and Assisted Reproductive Technologies, Al-Nahrain University, Baghdad, Iraq. The study population included men with both normal and abnormal semen parameters to ensure a diverse representation of fertility profiles. The participants in this study were divided into two groups based on their semen analysis results: 1- Normospermia group : This group (n = 20) included participants with normal semen parameters according to WHO’s reference ranges. All individuals in this group were non-smokers. 2- Sperm disorders group : This group (n = 45) comprised participants with abnormal seminal profile (oligospermia n = 14, asthenospermia n = 9, teratospermia n = 12, and OAT n = 10). All individuals in this group had a history of infertility of varying durations, as documented in their medical records. Sample collection Semen samples were collected from participants by masturbation after 3–5 days of abstinence, in accordance with WHO guidelines. Semen specimens were collected into sterile, wide-mouthed plastic containers provided by the center to maintain sample integrity and minimize contamination. Inclusion and exclusion criteria Inclusion criteria include couples with male factor infertility and was between 18-50 years of age. Females with tubal factor or unexplained infertility were also included. Exclusion criteria include wives with endometriosis, PCOS, diminished ovarian reserve or ovulatory dysfunction, male with chronic disease (diabetes mellitus, hypertension, endocrine disease, etc.) and testicular varicosity . Demographic data A detailed questionnaire on age, body weight, body height, duration of infertility, smoking and medical/surgical drug histories was taken from all cases. Detailed data about their female partners, including age, weight, height, and significant medical, surgical, or pharmacological history were also recorded. Sample preparation Semen plasma was collected through low-speed centrifugation (500 × g) for 10 min to prevent cell lysis. The supernatant was then centrifuged at (10,000 × g) for 5 min to remove the remaining cellular debris. The clarified seminal plasma obtained from this high-speed centrifugation was used directly for the isolation of cfDNA. DNA extraction The extraction of cfDNA from seminal plasma was achieved using the Presto™ cfDNA Extraction Kit (Geneaid, Cat. No. CF100), following the manufacturer’s protocol with minor modifications. Proteinase K and CF1 Buffer containing carrier RNA were added to 400 μL of seminal plasma sample and incubated at 60°C for 30 minutes to ensure complete lysis. This was followed by the addition of CF2 Buffer which contain isopropanol to facilitate DNA binding. The mixture then passed through isolation column using centrifugation, followed by washing with W1 and Wash Buffers. The cfDNA then eluted from the column with 50 μL of DNase-free water and stored at -70°C until further analysis. Quantitative Real-Time PCR Assay (qRT-PCR) and cfDNA quantification The seminal cfDNA was quantified by quantitative real-time PCR using the PerfectStart ® Green qPCR SuperMix (AQ601-V2), following the manufacturer’s instructions. The human growth differentiation factor (hGDF) gene was used as the amplification target, with the following primers: forward 5′-CGCAGAGGTCAGGAAACTGTC-3′ and reverse 5′-GGCAGGTACACATGACGGTCT-3′. Amplification was carried out using a real-time PCR system (Analytik Jena/qTOWER) under the following thermocycler protocol: an initial denaturation at 95°C for 30 seconds, followed by 40 cycles of denaturation at 95°C for 5 seconds and annealing/extension at 60°C for 30 seconds. Fluorescence data were collected during the extension phase of each cycle. A standard curve was prepared by amplifying five different known DNA concentrations (42, 4.2, 0.42, 0.042, and 0.0042 ng/μl) under the same qPCR conditions to determine the seminal cfDNA concentration. The log10 of the standard concentrations was plotted against the corresponding Ct values to construct the standard curve. Ct values obtained from seminal plasma samples were then applied to this curve to calculate the relative cfDNA concentrations in each sample. Estimation of total antioxidant capacity Seminal plasma TAC was estimated using a commercially available colorimetric assay kit (Solarbio, Cat. No. BC1315), according to the manufacturer’s protocol. The assay is based on the conversion of ferric-tripyridyltriazine (Fe 3+ –TPTZ) to the blue-coloured ferrous form (Fe 2+ –TPTZ) by antioxidants present in the sample under low pH. The absorbance of the resulting colour, measured spectrophotometrically at 593 nm, is proportional to TAC. A working reagent was prepared by mixing Reagent I, Reagent II, and Reagent III in a 7:1:1 ratio and preincubated at 37°C for 10 minutes. For each reaction, 6 μL of sample are mixed with 180 μL of the working reagent and 18 μL of distilled water and incubated at 37°C for 10 minutes (all measurements were done in triplicates). Absorbance was read at 593 nm using a microplate reader, with blanks prepared using distilled water in place of sample. A standard curve was generated using serial dilutions of FeSO 4 , and TAC values were expressed as μmol/mL using the formula: TAC = 34 × x, where x is the concentration obtained from the standard curve. Statistical analysis The collected data were analyzed using the statistical package of IBM SPSS-30 (IBM Statistical Packages for Social Sciences- version 30, Chicago, IL, USA). The significance of difference of different means (quantitative data) were tested using Students-t-test for difference between two independent means or ANOVA test for difference among more than two independent means. The significance of differences of different percentages (qualitative data) were tested using Pearson Chi-square test (χ 2 -test) with application of Yate’s correction. Statistical significance was considered whenever the P value was equal or less than 0.05. Pearson correlation was calculated for the correlation between two quantitative variables with its t-test for testing the significance of correlation. Results The current study included 65 couples undergoing ICSI. Among them, 45 couples diagnosed with male factor infertility were categorized into the sperm disorder group, while the remaining 20 couples, who demonstrated normal semen parameters, comprised the normospermia group. There was a statistically significant difference regarding the age-distribution between groups as demonstrated in Table 1 ( p = 0.034). A higher proportion of men aged ≥40 years was observed in the sperm disorder group (35.6%) compared to the normospermia group (5.0%), while the 25–29 age group was more prevalent among normospermic males (50.0% vs. 22.2%). The mean age of the sperm disorder group was also significantly higher (36.1 ± 6.4 years) than that of the normospermia group (30.6 ± 4.7 years, p = 0.001). Although the average BMI in the sperm disorder group was slightly higher, the difference was not significant. Additionally, 55.6% of the sperm disorder group was smoker, while no one in the normospermia group was smoker. Table 1. Comparison of male demographic and health characteristics between sperm disorder and normospermia groups. Male characteristics Sperm disorder Normospermia P value NO. % NO. % Male age (years) 25---29 10 22.2 10 50.0 0.034 * 30---34 10 22.2 5 25.0 35---39 9 20.0 4 20.0 =>40 years 16 35.6 1 5.0 Mean ± SD 36.1 ± 6.4 30.6 ± 4.7 0.001 # Range (25-47) (25-40) Male BMI (Kg/m 2 ) Normal (18.5-24.9) 13 28.9 9 45.0 0.329 Overweight (25-29.9) 22 48.9 9 45.0 Obese (=>30) 10 22.2 2 10.0 Mean ± SD 26.80 ± 3.51 25.93 ± 2.98 0.342 Range (18.6-33.6) (20.9-32.1) Sterility duration (years) 1---4 10 22.2 - - - 5---9 23 51.1 - - 10-15 years 12 26.7 - - Mean ± SD 6.93 ± 3.04 - Range (3-15) - Smoking status Smoker 25 55.6 - - - Non-smoker 20 44.4 - - * Significant difference between percentages using Pearson Chi-square test (χ 2 -test) at 0.05 level. # Significant difference between two independent means using Students-t-test at 0.05 level. The duration of sterility was assessed in the sperm disorder group, showing an average of 6.93 ± 3.04 years, with a range between 3 and 15 years. More than half (51.1%) had experienced sterility 5–9 years, followed by 10–15 years (26.7%) and lastly 1–4 years (22.2%). Significant variations in seminal biomarkers were evident between the two groups. As shown in Table 2 , the mean cfDNA concentration was substantially elevated in the sperm disorder group (3.482 ± 0.936 μg/ml) compared to the normospermia group (0.631 ± 0.454 μg/ml, p = 0.0001). In contrast, TAC was significantly lower in the sperm disorder group (1260.42 ± 251.29 μM/ml) than in the normospermia group (1847.80 ± 70.71 μM/ml, p = 0.0001). These findings strongly suggest that increased OS and cfDNA are closely linked to impaired semen quality. Table 2. Comparison of cfDNA and TAC levels between sperm disorder and normospermia groups. Analysis Sperm disorder Normospermia P value CfDNA (μg/ml) 3.482 ± 0.936 (1.230-5.370) 0.631 ± 0.454 (0.02-1.522) 0.0001 # TAC (μM/ml) 1260.42 ± 251.29 (817-1760) 1847.80 ± 70.71 (1748-1981) 0.0001 # # Significant difference between two independent means using Students-t-test at 0.05 level. Further analysis ( Table 3 , Figures 1 & 2 ) revealed notable differences in cfDNA and TAC levels across various types of sperm abnormalities. Men with OAT exhibited the highest cfDNA concentration (4.476 ± 0.552 μg/ml), followed by those with asthenospermia (3.850 ± 0.922 μg/ml), teratospermia (3.120 ± 0.529 μg/ml), and oligospermia (2.781 ± 0.735 μg/ml). These differences were highly significant ( p = 0.0001, ANOVA). Table 3. Comparison of seminal cfDNA and TAC levels across different seminal analysis statuses. Seminal analysis status CfDNA (μg/ml) TAC (μM/ml) Sperm disorder Oligospermia 2.781 ± 0.735 1490.928 ± 194.081 Asthenospermia 3.849 ± 0.922 1167.888 ± 172.623 Teratospermia 3.120 ± 0.529 1309.583 ± 127.729 Mixed (Oligo-Astheno-Teratospermia) 4.476 ± 0.552 962.000 ± 120.433 Normospermia 0.631 ± 0.454 1847.800 ± 70.714 P value 0.0001 ^ 0.0001 ^ ^ Significant difference among more than two independent means using ANOVA-test at 0.05 level. Figure 1. Comparison of mean seminal cfDNA levels across different types of sperm disorders and normospermia. Figure 2. Comparison of mean TAC levels across different types of sperm disorders and normospermia. Conversely, TAC levels showed a decreasing trend with increasing severity of sperm abnormalities. The highest TAC was observed in the oligospermia group (1490.93 ± 194.08 μM/ml), followed by teratospermia (1309.58 ± 127.73 μM/ml), asthenospermia (1167.89 ± 172.62 μM/ml), and the lowest in the OAT subgroup (962.00 ± 120.43 μM/ml). These differences were also statistically significant ( p = 0.0001, ANOVA), supporting an inverse relationship between OS and semen quality. Building on these biomarker disparities, Table 4 explores how cfDNA correlates with ICSI outcomes. A clear and consistent trend emerged: higher cfDNA levels were associated with lower-quality embryos. In the sperm disorder group, grade I embryos were linked to the lowest cfDNA concentration (2.195 ± 0.66 μg/ml), while grade III embryos had the highest (4.023 ± 0.85 μg/ml, p = 0.0001). This pattern was also observed in the normospermia group but at significantly lower cfDNA levels. Table 4. Comparison of seminal cfDNA levels in relation to ICSI outcomes in sperm disorder and normospermia groups. ICSI outcomes CfDNA (μg/ml) P value Sperm disorder Normospermia Embryo grade G I 2.195 ± 0.662 0.053 ± 0.048 0.0001 # G II 3.368 ± 0.672 0.580 ± 0.328 0.0001 # G III 4.023 ± 0.858 0.682 ± 0.024 0.0001 # P value 0.0001 ^ 0.005 ^ Fertilization Yes 3.410 ± 1.029 0.474 ± 0.340 0.0001 # No 3.681 ± 0.603 1.257 ± 0.272 0.0001 # P value 0.396 0.0001 # Pregnancy (for fertilized only) Yes 2.90 ± 1.153 0.372 ± 0.242 0.0001 # No 3.75 ± 0.801 0.917 ± 0.393 0.0001 # P value 0.017 # 0.007 # Miscarriage (for pregnant only) Yes (Abortion) 3.230 ± 1.085 0.675 ± 0.035 0.002 # No 1.768 ± 0.466 0.317 ± 0.221 0.0001 # P value 0.048 # 0.049 # # Significant difference between two independent means using Students-t-test at 0.05 level. ^ Significant difference among more than two independent means using ANOVA-test at 0.05 level. The impact of cfDNA on fertilization success followed a similar pattern. In the normospermia group, men with successful fertilization had markedly lower cfDNA levels (0.474 ± 0.34 μg/ml) compared to those with failed fertilization (1.257 ± 0.27 μg/ml, p = 0.0001). Although this trend was also seen in the sperm disorder group, it did not reach statistical significance. Pregnancy outcomes further substantiated cfDNA’s predictive value. In the sperm disorder group, men whose partners achieved pregnancy had lower cfDNA levels (2.90 ± 1.15 μg/ml) compared to those who did not conceive (3.75 ± 0.80 μg/ml, p = 0.017). Similarly, in the normospermia group, successful pregnancies were associated with significantly lower cfDNA levels (0.372 ± 0.24 μg/ml) than unsuccessful ones (0.917 ± 0.39 μg/ml, p = 0.007). Miscarriages were also linked to elevated cfDNA concentrations in both groups. In the sperm disorder group, the mean cfDNA level was (3.230 ± 1.08 μg/ml) in miscarriage cases, compared to (1.768 ± 0.46 μg/ml) in pregnancies that progressed ( p = 0.048). In the normospermia group, miscarriage cases had a mean cfDNA level of (0.675 ± 0.03 μg/ml), while ongoing pregnancies showed lower levels (0.317 ± 0.22 μg/ml, p = 0.049). These findings suggest that excessive sperm DNA fragmentation may compromise embryo viability even after implantation. To complement cfDNA findings, Table 5 evaluates the role of TAC in ICSI success. Consistently, higher TAC levels correlated with favorable outcomes. For instance, among sperm disorder cases, grade I embryos were associated with the highest TAC (1549.42 ± 191.06 μM/ml), significantly surpassing those linked to grade III embryos (1137.15 ± 203.98 μM/ml, p = 0.017). A similar relationship was evident in the normospermia group, reinforcing the protective role of antioxidants in embryogenesis. Table 5. Comparison of TAC levels in relation to ICSI outcomes in sperm disorder and normospermia groups. ICSI outcomes TAC (μM/ml) P value Sperm disorder Normospermia Embryo grade G I 1549.428 ± 191.067 1845.250 ± 93.414 0.010 # G II 1265.076 ± 191.039 1865.130 ± 45.193 0.0001 # G III 1137.153 ± 203.988 1823.750 ± 108.389 0.055 P value 0.017 ^ 0.699 Fertilization Yes 1264.560 ± 249.492 1849.810 ± 73.210 0.0001 # No 1247.640 ± 268.711 1839.750 ± 69.014 0.004 # P value 0.849 0.807 Pregnancy (for fertilized only) Yes 1370.230 ± 255.063 1843.150 ± 71.298 0.0001 # No 1199.140 ± 227.860 1878.667 ± 90.335 0.005 # P value 0.050 # 0.468 Miscarriage (for pregnant only) Yes (Abortion) 1292.700 ± 215.984 1752.000 ± 5.657 0.081 No 1628.666 ± 224.020 1859.727 ± 64.289 0.001 # P value 0.039 # 0.043 # # Significant difference between two independent means using Students-t-test at 0.05 level. ^ Significant difference among more than two independent means using ANOVA-test at 0.05 level. Regarding fertilization, TAC levels were slightly higher in successful cases within both groups. In the sperm disorder group, fertilized cases had a mean TAC of (1264.56 ± 249.49 μM/ml), compared to (1247.64 ± 268.71 μM/ml) in non-fertilized cases, though this difference was not statistically significant ( p = 0.849). In the normospermia group, fertilized cases had a mean TAC of (1849.81 ± 73.21 μM/ml), while non-fertilized cases showed a slightly lower value of (1839.75 ± 69.014 μM/ml); again, the difference was not statistically significant ( p = 0.807). When examining pregnancy outcomes, TAC levels were again higher in successful pregnancies. In the sperm disorder group, pregnancies were associated with a mean TAC of (1370.23 ± 255.06 μM/ml), significantly higher than the (1199.14 ± 227.86 μM/ml) observed in non-pregnant cases (p = 0.050). On the other hand, the normospermia group showed no significant difference in TAC levels between successful pregnancies (1843.15 ± 71.29 μM/ml) and unsuccessful cases (1878.66 ± 90.33 μM/ml; p = 0.468). Furthermore, miscarriage analysis revealed that in the sperm disorder group, pregnancies that progressed successfully had significantly higher TAC levels (1628.66 ± 224.02 μM/ml) compared to miscarried cases (1292.70 ± 215.98 μM/ml, p = 0.039). In the normospermia group, a similar significant difference was noted, with ongoing pregnancies having a mean TAC of (1859.72 ± 64.289 μM/ml), compared to (1752.00 ± 5.657 μM/ml) in miscarriage cases ( p = 0.043). Finally, Table 6 presents the correlations between cfDNA, TAC, and conventional semen parameters. In the sperm disorder group, cfDNA levels showed significant negative correlations with progressive motility (grades A and B; p < 0.01) and a significant positive correlation with immotile sperm (grade D; p = 0.0001). Although a negative association was observed between cfDNA and sperm morphology, it did not reach statistical significance ( p = 0.088). No significant correlations were found between cfDNA and sperm concentration, age, or BMI. Table 6. Correlation of seminal cfDNA and TAC levels with male characteristics and semen parameters in sperm disorder and normospermia Groups. CfDNA (μg/ml) TAC (μM/ml) Sperm disorder (n = 45) Normospermia (n = 20) Sperm disorder (n = 45) Normospermia (n = 20) Male age (years) r 0.116 0.025 0.011 -0.088 P 0.449 0.916 0.942 0.713 Male BMI (Kg/m 2 ) r -0.040 -0.053 -0.165 -0.147 P 0.793 0.823 0.280 0.537 Concentration (m/ml) r 0.016 -0.210 0.004 -0.041 P 0.917 0.374 0.980 0.864 Motility% A r -0.491 ** 0.102 0.496 ** -0.143 P 0.0001 0.669 0.0001 0.546 Motility% B r -0.439 ** -0.218 0.550 ** -0.086 P 0.003 0.356 0.0001 0.720 Motility% C r -0.160 0.341 0.150 0.111 P 0.295 0.141 0.324 0.642 Motility% D r 0.621 ** -0.251 -0.700 ** 0.143 P 0.0001 0.286 0.0001 0.547 Morphology% r -0.257 -0.107 0.434 ** -0.152 P 0.088 0.653 0.003 0.521 CfDNA (μg/ml) r 1 1 -0.785 ** -0.040 P 0.0001 0.867 TAC (μM/ml) r -0.785 ** -0.040 1 1 P 0.0001 0.867 * Correlation is significant at the 0.05 level. ** Correlation is highly significant at the 0.01 level. Conversely, TAC levels demonstrated significant positive correlations with progressive motility (grades A and B; p < 0.001) and morphology ( p = 0.003), along with a significant negative correlation with immotile sperm (grade D; p = 0.0001). However, TAC levels showed no significant correlation with sperm concentration, age, or BMI. In the normospermia group, none of the correlations between cfDNA or TAC and semen parameters, age, or BMI reached statistical significance, likely due to the relatively uniform semen quality and demographic characteristics within that cohort. Discussion The current study included 65 couples who were candidates for ICSI. Of these, 45 couples, who had male factor infertility, were assigned to the sperm disorder group, while 20 couples constituted the normospermia group, exhibiting normal semen parameters. For consistency, couples in which the female partner had normal fertility evaluation were selected to avoid potential confounder of female infertility. Female partners who had any documented reproductive abnormalities, such as endometriosis, diminished ovarian reserve, and other gynecological conditions, were not included in the study. This model was used to concentrate on the impact of male seminal factors, specifically levels of cfDNA and TAC on ICSI outcomes. The difference in fertilization rates and pregnancy/miscarriage outcomes were compared between two male groups to explore the effects of sperm quality and OS indicators on the success of assisted reproduction. Demographic analysis of the study population ( Table 1 ) revealed a significant difference between the groups in the mean male age. The mean age in the sperm disorder group was significantly higher than that of the normospermia group. However, it is important to note that the average duration of sterility among males in the sperm disorder group was 6.9 ± 3.04 years. This indicates that the sperm abnormalities could present at a younger age and were not a direct consequence of aging. Therefore, while advancing age is an important factor influences semen quality, 25 , 26 the early onset of infertility in those males suggest that intrinsic seminal defects played a major role in their reproductive dysfunction. Importantly, the effect of paternal age on ICSI outcomes remains controversial. Some studies have stated that the paternal age has a negative correlation with ICSI success rate, 25 , 27 , 28 while others have found that the advanced paternal age has no effect on the outcomes of ICSI cycles. 29 , 30 The analysis of BMI revealed no significant difference between the two groups. The mean BMI for sperm disorder group was (26.80 ± 3.51 kg/m 2 ) compared to (25.93 ± 2.98 kg/m 2 ) in the normospermia group ( p = 0.342). The comparable BMI values suggest no appreciable contribution of the weight status to the differences observed in sperm parameters, semen biomarkers, and ICSI outcomes. Regarding smoking status in the study population, all participants were non-smokers in the normospermia group, whereas a large proportion (55.6%) in the sperm disorder group reported smoking. Studies have demonstrated that smoking compromises sperm quality by increasing OS, increasing DNA damage, and inducing cell apoptosis. 31 – 33 Therefore, smoking could contribute partially to the observed differences in seminal oxidative balance and ICSI outcomes. Our study demonstrated that men with sperm abnormalities exhibited significantly elevated levels of seminal cfDNA compared to normospermic individuals (3.482 ± 0.936 μg/ml vs. 0.631 ± 0.454 μg/ml; p = 0.0001), as shown in Table 2 . This finding is in agreement with several studies that reported a significant relationship between increased levels of seminal cfDNA and subnormal sperm parameters in infertile men. According to Javidmehr et al. (2024), 34 higher cfDNA levels are consistently found in men with sperm abnormalities such as oligozoospermia, teratozoospermia, and azoospermia, compared to normozoospermic controls. These findings were supported by the work of Mbaye et al. (2021) 35 who reported that significantly elevated cfDNA levels in men with poor sperm count, morphology, and high DNA fragmentation index (DFI), suggesting that cfDNA reflects underlying sperm chromatin instability and apoptosis. Similarly, Di Pizio et al. (2020) 21 found that cfDNA concentrations were markedly elevated in men with sperm disorders compared to normospermic men (2.09 μg/mL versus 1.18 μg/mL), and positively correlated with the severity of sperm defects. The work by Costa et al. (2017) 36 also highlighted that cfDNA levels (measured by PicoGreen fluorochrome) correlated inversely with standard semen quality metrics such as motility and morphology. It is noteworthy to mention that cfDNA could be released into the seminal plasma by different biological processes, mainly apoptosis, necrosis, and a particular process named NETosis. 16 These cellular events often occur in response to abnormal spermatogenesis or impaired maturation processes, particularly in men with oligozoospermia, teratozoospermia, or azoospermia. Di Pizio et al. (2020) 21 observed that men with teratozoospermia exhibited elevated cfDNA levels than men with normal sperm parameters. They proposed that spermatogenic impairment may activate cellular checkpoints that lead to apoptotic DNA fragmentation and subsequent release of cfDNA. The released cfDNA itself could have a detrimental effect on sperm parameters by triggering sperm DNA fragmentation. Aitken et al. (2020) 37 proposed that extracellular free DNA can induce DNA fragmentation in sperm through nuclease activation, thereby contributing to a feedback loop of genetic damage and infertility. The role of OS as a contributor to elevated levels of cfDNA was demonstrated experimentally by Costa et al. (2017). 36 They demonstrated that exposing semen samples to paraquat, a ROS inducer, led to a significant increase in cfDNA levels, coupled with reduced sperm viability, motility, and morphology. These results suggest that cfDNA not only originates from sperm degeneration but also serves as a sensitive indicator of oxidative damage in the male reproductive system. Spermatozoa are uniquely vulnerable to oxidative damage due to high polyunsaturated fatty acid (PUFA) content in their membranes, scarce cytoplasmic volume, limited DNA repair capacity, and, in defective sperm, improper chromatin packaging that exposes DNA to oxidative damage. 38 , 39 According to Oliva et al. (2006), 40 infertile men exhibited elevated histone: protamine ratio, which results in insufficient chromatin compaction and increases vulnerability to oxidative damage. A finding by Sakkas and Alvares 41 emphasizes that oxidative injury to spermatozoa results in increased DNA strand breaks, which may subsequently impair fertilization, embryo development, and pregnancy. Our study demonstrated a significantly lower TAC in men with sperm abnormalities compared to normospermic men (1260.42 ± 251.29 μM/ml vs. 1847.80 ± 70.71 μM/ml; p = 0.0001), as shown in Table 2 . This decline reflects a compromised antioxidant defense system in the sperm disorder group, underscoring the role of OS in male infertility. As a cumulative parameter of both enzymatic and non-enzymatic antioxidants in seminal plasma, TAC reflects the body’s ability to neutralize ROS, which are known to cause lipid peroxidation, DNA fragmentation, and reduced sperm viability. This finding supports Tremellen’s (2008) 42 OS model of male infertility, which postulates that when ROS generation exceeds antioxidant neutralization, oxidative damage undermines reproductive potential. This mechanism is strongly supported by findings from Pahune et al. (2013), 43 Giulini et al. (2009), 44 and Demir and Özdem (2022), 45 who demonstrated that infertile men, especially those with combined sperm abnormalities exhibited significantly lower TAC levels than normospermic individuals, aligning well with our observations. Additional corroboration comes from Saleh et al. (2018), 13 who showed that infertile men had significantly lower TAC compared to healthy men. In addition, they reported that infertile men have a significant high level of caspase-3 activity, an indicator of apoptosis, implying that oxidative damage may trigger cell death pathways detrimental to spermatogenesis. Further, Alahmar et al. (2021) 46 emphasized that men with idiopathic oligoasthenozoospermia show particularly diminished TAC levels and high DNA fragmentation, underscoring the central role of OS in their pathophysiology. The concurrent elevation of cfDNA and reduction of TAC in our sperm disorder group reinforces this mechanistic link, suggesting that OS not only contributes to defective spermatogenesis but may also mediate DNA instability and impaired fertilization potential. The reduced TAC likely plays a pivotal role in the poor semen quality and ICSI outcomes seen in this cohort. A stratified subgroup analysis was conducted to investigate the differences in cfDNA and TAC across groups of sperm abnormalities, as shown in Table 3 , Figures 1 & 2 . Oligospermia was associated with a cfDNA concentration of (2.78 ± 0.73 μg/ml) and the highest TAC among the disorder groups at (1490.93 ± 194.08 μM/ml), indicating relatively limited oxidative disruption. These results are in line with findings by Mbaye et al. (2021), 35 who reported elevated cfDNA levels in oligospermic men (1.26 ± 0.22 μg/ml) compared to normospermic controls (0.09 ± 0.01 μg/ml). In terms of antioxidant defense, Eroglu et al. (2014) 47 similarly observed significantly reduced TAC in oligospermic patients compared to normospermic individuals, suggesting that even isolated sperm count deficiencies are linked to early OS and DNA damage. In teratospermia, cfDNA levels reached (3.12 ± 0.52 μg/ml), while TAC dropped to (1309.58 ± 127.72 μM/ml). These findings reflect increased oxidative damage and are supported by Di Pizio et al. (2020), 21 who documented significantly higher cfDNA in teratozoospermic men (1.80 ± 0.33 μg/ml) than in normospermic individuals (1.29 ± 0.26 μg/ml). Regarding antioxidant status, Demir and Özdem (2022) 45 also reported lower TAC levels in men with teratospermia (median 1.57 mmol/L) compared to fertile controls (1.74 mmol/L), reinforcing the association between morphological sperm defects and oxidative imbalance. In asthenospermia, cfDNA increased further to (3.85 ± 0.92 μg/ml), and TAC declined to (1167.88 ± 172.62 μM/ml), reflecting compromised sperm motility and redox status. Mbaye et al. (2021), 35 observed that the level of cfDNA in males with asthenozoospermia is significantly higher than normospermic males. Additionally, Alahmar et al. (2021) 46 found significantly elevated DFI and reduced TAC levels in men with poor motility, suggesting a shared oxidative mechanism. It was found that ROS-induced mitochondrial DNA damage reduces ATP production and energy supply, thereby impairing sperm motility. 48 This is further supported by Khosrowbeygi and Zarghami (2008), 49 who reported a positive correlation between TAC and sperm motility, implying that reduced antioxidant defenses underlie motility impairments. The most severe profile was observed in men with OAT, who had the highest seminal cfDNA levels at (4.47 ± 0.55 μg/ml) and the lowest TAC values at (962.00 ± 120.43 μM/ml). These values reflect a compounded oxidative burden resulting from the simultaneous presence of three sperm abnormalities. It has been reported that abnormal sperms tend to generate ROS and further compromising the seminal antioxidant defense. 9 , 48 Javdimehr et al. (2025) 50 reported that men with OAT had significantly higher seminal cfDNA levels compared to those with oligoasthenospermia, oligoteratozoospermia, nonobstructive azoospermia, and normozoospermia. Although Di Pizio et al. (2021) 21 did not specifically analyze OAT, they did report that azoospermic patients, often considered even more severe, had cfDNA levels as high as (3.65 ± 0.88 μg/ml), reinforcing the trend of escalating cfDNA with increasing pathology. For TAC, Demir and Özdem (2022) 45 showed that OAT patients had the lowest median TAC (1.19 mmol/L), and Giulini et al. (2009) 44 reported even more dramatic reductions in moderate (0.83 ± 0.36 mmol/L) and severe (0.70 ± 0.43 mmol/L) OAT cases. Although direct DNA fragmentation testing was not performed in this study, the elevated cfDNA levels in the sperm disorder group provide a strong indirect marker. cfDNA is released from apoptotic and DNA-damaged sperm and has been correlated with DFI in infertile men. This relationship is confirmed by several studies which demonstrated that patients with elevated DNA fragmentation had significantly higher levels of seminal cfDNA, supporting the validity of cfDNA as a surrogate marker for sperm genomic instability. 20 , 21 , 37 Furthermore, the sperm disorder group exhibited significantly reduced TAC, reinforcing the presence of OS as a contributing factor. As Agarwal et al. (2020) 51 and Giulini et al. (2009) 44 have shown, oxidative damage is a major mechanism behind chromatin instability, with reduced TAC directly linked to impaired fertilization and embryo development. The relationship between sperm oxidative biomarkers and ICSI outcomes is clearly illustrated in Tables 4 & 5 . Our study reveals that fertilization rates were statistically comparable between the normospermia group (80.0%) and the sperm disorder group (75.6%) ( p = 0.695). The lack of significant difference in fertilization rates despite differing sperm quality profiles can be explained by the nature of ICSI, where natural selection processes are bypassed. Sperms are selected based on motility and morphology under the microscope, which does not reveal their underlying genomic integrity. As noted by Aitken and De Iuliis (2007), 52 ICSI enables the fertilization of oocytes using sperm that may be genomically compromised. Bungum et al. (2007) 22 added that even sperm with DNA damage can successfully form pronuclei and initiate early embryonic development in ART settings, though their developmental potential may be impaired. This view is supported by Sun et al. (2018) 23 and Al Omrani et al. (2018), 24 who reported that high sperm DNA fragmentation had no statistically significant effect on fertilization rates in ICSI procedures, reinforcing the idea that fertilization may proceed despite compromised DNA integrity. Similarly, Henkel et al. (2003), 53 Li et al. (2024), 54 and Sivanarayana et al. (2014) 55 reported that high DNA fragmentation does not significantly impair fertilization rates in ICSI, further supporting the notion that fertilization may be an inadequate endpoint for assessing the true reproductive consequences of genomic instability, which may manifest later during embryo development or implantation. However, other studies present contrasting evidence: Lopes et al. (1998) 56 and Huang et al. (2005) 57 found that increased DNA fragmentation was negatively associated with fertilization success, suggesting that extensive genomic damage may still hinder ICSI outcomes at this early stage. Virro et al. (2004) 58 observed that DNA fragmentation levels above 30% were associated with significantly reduced fertilization rates in IVF, emphasizing that the fertilization outcome may be more sensitive to DNA quality in procedures where natural selection remains partially intact. Additionally, a study by Ribas-Maynou et al. (2022) 59 reported that sperm DNA fragmentation reduces fertilization rates and delays embryo development in ICSI cycles. While ICSI can overcome mechanical barriers to fertilization, it does not eliminate the impact of sperm DNA damage on embryo development and pregnancy. It has been demonstrated that DNA-fragmented sperm may appear morphologically normal and motile, increasing the chance of being selected during ICSI and potentially contributing to compromised embryo development and early pregnancy loss. 5 , 60 According to our study, embryo quality was inversely related to cfDNA levels Table 4 . Grade I embryos were associated with the lowest cfDNA concentration (2.19 ± 0.662 μg/ml), while grade III embryos were linked to the highest levels (4.02 ± 0.858 μg/ml; p = 0.0001). This finding is consistent with Ribas-Maynou et al. (2022), 59 who observed that sperm DNA damage negatively impacts blastocyst formation and embryo development. Similarly, Simon et al. (2011) 61 reported that elevated sperm DNA fragmentation is associated with the generation of poor-quality embryos, thereby reducing the likelihood of achieving successful implantation. Seli et al. (2004) 62 found that high levels of sperm DNA fragmentation adversely affected blastocyst development in IVF cycles, highlighting the relevance of sperm genomic integrity during early embryogenesis. In addition, Virro et al. (2004) 58 demonstrated that high sperm DNA damage had reduced blastocyst formation rates in IVF/ICSI cycles. Borini et al. (2006) 63 further emphasized that sperm DNA damage compromises embryo quality even post-implantation, potentially affecting later developmental stages in ICSI-derived pregnancies. Moreover, Henkel et al. (2003) 53 explained that spermatozoa with high DNA fragmentation may appear functionally competent during fertilization but later impair embryonic progression once the paternal genome becomes transcriptionally active, offering a mechanistic rationale for the observed reduction in embryo quality. Seminal cfDNA levels also demonstrated strong predictive value for pregnancy success. In the sperm disorder group, men whose partners achieved pregnancy had significantly lower cfDNA levels than those who did not (2.90 ± 1.153 vs. 3.75 ± 0.801 μg/ml; p = 0.017). A similar trend was observed in the normospermia group (0.372 ± 0.242 vs. 0.917 ± 0.393 μg/ml; p = 0.007), underscoring the reliability of cfDNA as a marker of sperm genomic integrity. Our findings align with previous research demonstrating that elevated sperm DNA fragmentation is negatively associated with pregnancy rates in ICSI cycles. 64 – 69 Importantly, unlike many previous studies that conclude ICSI success at the point of achieving clinical pregnancy, our investigation extended the follow-up period to include miscarriage outcomes. We believe that clinical pregnancy alone may be an insufficient endpoint, as it does not capture the full trajectory of reproductive success. By monitoring participants through early gestation, we were able to evaluate the risk of pregnancy loss, a more definitive and biologically meaningful outcome of ICSI. This approach allowed us to link seminal oxidative markers, such as cfDNA and TAC, not only to fertilization and implantation but also to the ability to sustain a viable pregnancy. Consequently, miscarriage rate in our view represents a more comprehensive and clinically relevant indicator of ICSI outcome. In our study, miscarriage outcomes showed a strong link to cfDNA levels. Table 4 indicates that ongoing pregnancies were associated with significantly lower cfDNA levels (1.76 ± 0.466 μg/ml) than pregnancies that ended in loss (3.23 ± 1.085 μg/ml; p = 0.048). These findings mirror those reported by Zini et al. (2008) 70 and Virro et al. (2004), 58 who showed that sperm DNA fragmentation is a key predictor of miscarriage following ART procedures. Further support comes from Benchaib et al. (2003), 68 who found that DFI greater than 15% were significantly associated with elevated miscarriage risk in ICSI patients. Similarly, Boe-Hansen et al. (2006), 71 demonstrated that while clinical pregnancy can still be achieved, the likelihood of carrying to term may be reduced when DFI approaches or exceeds 27%. Additionally, Lin et al. (2008), 72 highlighted that DNA fragmentation exerts its most pronounced effect during post-implantation stages, significantly increasing miscarriage rates while showing limited influence on initial pregnancy establishment. As we mentioned earlier, in ICSI procedure, the sperm selection is based on morphology and motility, which do not reflect its genomic integrity. In a meta-analysis study, Zhao et al. (2014), 73 reported a strong association between elevated sperm DNA fragmentation and increased miscarriage rates in ICSI, but not IVF, highlighting the consequences of bypassing natural sperm selection. The mechanism by which DNA damage contributes to pregnancy failure may be delayed in its manifestation. It has been reported that the embryonic genome remains transcriptionally silent until after the second cleavage division, suggesting that abnormalities in the paternal genome may not influence fertilization or early embryonic development but become apparent at later stages. 74 As such, sperm with substantial DNA damage may successfully fertilize oocytes and form early-stage embryos in vitro, yet fail to support proper development in utero, ultimately leading to miscarriage. TAC levels were also associated with key ICSI outcomes, as shown in Table 5 . Higher TAC was significantly associated with better embryo quality, as men whose partners produced grade I embryos had the highest mean TAC (1549.42 ± 191.067 μM/ml), while grade III embryos were linked to the lowest TAC (1137.15 ± 203.988 μM/ml; p = 0.017). These results are in line with Greco et al. (2005), 75 who found that antioxidant treatment reduced sperm DNA fragmentation and improved embryo morphology in ICSI cycles. Scaruffi et al. (2021) 76 similarly reported enhanced blastocyst development and pregnancy rates in antioxidant-treated men undergoing ART. While TAC did not significantly influence fertilization rates, it was predictive of pregnancy. In the sperm disorder group, TAC was higher in those who achieved pregnancy (1370.23 ± 255.063 μM/ml) compared to non-pregnant individuals (1199.14 ± 227.860 μM/ml; p = 0.050). Miscarriage data showed even more pronounced differences: ongoing pregnancies were associated with significantly higher TAC (1628.66 ± 224.020 μM/ml) than those that ended in loss (1292.70 ± 215.984 μM/ml; p = 0.039). This pattern was similarly observed in the normospermia group ( p = 0.043). These findings align with Gupta et al. (2021) 77 and Alahmar et al. (2018), 78 who documented the relationship between oxidative imbalance, reduced TAC, and increased risk of early pregnancy loss. Together, these findings underscore that TAC is not only a marker of sperm quality but also a predictive indicator of ICSI success. Given that antioxidant systems in seminal plasma function to neutralize ROS and protect sperm DNA from oxidative damage, their depletion can compromise reproductive outcomes. As supported by Agarwal et al. (2020) 51 and Tremellen (2008), 42 correcting this imbalance through antioxidant therapies or lifestyle modifications may enhance embryo viability, reduce miscarriage, and improve ART success rates, especially in men with high OS profiles. In the sperm disorder group, cfDNA levels demonstrated significant negative correlations with progressive motility types A and B (r = –0.491, p = 0.0001; r = –0.439, p = 0.003) and a strong positive correlation with immotile sperm (type D) (r = 0.621, p = 0.0001) ( Table 6 ). These results indicate that higher cfDNA, suggestive of greater DNA fragmentation, is associated with impaired sperm motility. This relationship aligns with the findings of Benchaib et al. (2003), 68 Appasamy et al. (2007), 79 Le et al. (2019), 80 and Al Omrani et al. (2018), 24 who documented that increased DNA fragmentation correlates negatively with sperm motility. Costa et al. (2017) 36 further linked high seminal cfDNA to motility and morphology impairments. However, cfDNA did not show statistically significant correlations with sperm concentration or morphology. This is consistent with Liu et al. (2023) 81 and Al Omrani et al. (2018), 24 who found no association between DNA damage and morphology. Nevertheless, Liu et al. (2023) 81 and Al Omrani et al. (2018) 24 reported negative correlations between DFI and concentration. Similarly, Le et al. (2019) 80 did observe a negative association between DNA damage and sperm head morphology, suggesting variability across cohorts. Regarding demographic parameters, cfDNA levels were not significantly correlated with age and BMI ( Table 6 ). However, contrasting evidence was reported by Shi et al. (2018), 82 Das et al. (2013), 83 Rybar et al. (2011), 84 and Chua et al. (2023), 85 all of whom found a positive correlation between age and DNA fragmentation. Likewise, studies by Kort et al. (2006), 86 La Vignera et al. (2012), 87 and Fariello et al. (2012) 88 reported a positive correlation between BMI and DFI. TAC levels in the sperm disorder group showed significant positive correlations with progressive motility types A and B (r = 0.496 and 0.550, both p = 0.0001) ( Table 6 ), and with sperm morphology (r = 0.434, p = 0.003), while showing a strong inverse correlation with immotile sperm (type D) (r = –0.700, p = 0.0001). These findings support the antioxidant role of seminal plasma in preserving motility and structural integrity. Our results align with previous research from Khosrowbeygi et al. (2007), 89 Koca et al. (2003), 90 Demir & Ozdem (2022), 45 Pahune et al. (2013), 43 Gupta et al. (2020), 77 Eroglu et al. (2014), 47 and Giulini et al. (2009), 44 all of whom found that TAC is positively correlated with motility and morphology. TAC showed no significant correlations with sperm concentration, age, and BMI, which is consistent with Appasamy et al. (2007) 79 and El-Gazzar et al. (2023). 91 Nonetheless, Gupta et al. (2020), 77 Giulini et al. (2009), 44 and Eroglu et al. (2014) 47 did report a positive association between TAC and sperm concentration. A strong negative correlation was observed between cfDNA and TAC (r = –0.785, p = 0.0001), supporting the role of OS in compromising DNA integrity. This is in agreement with Liu et al. (2023), 81 who demonstrated an inverse association between TAC and DNA fragmentation, and indirectly supported by the OS model proposed in studies like Costa et al. (2017). 36 Lastly, in the normospermia group, no significant correlations were detected between cfDNA, TAC, and semen parameters ( Table 6 ). This may reflect the relatively stable redox environment and lower variability in seminal biomarkers among men with normal semen profiles, limiting the detectability of such associations in this group. This study has some limitations that should be considered when interpreting the results. First, it was conducted at a single center with a relatively modest sample size, which may limit the generalizability of the findings to broader populations. Second, although seminal cfDNA was employed as a surrogate marker, direct measurement of the sperm DFI would have provided more robust validation of DNA integrity assessments. Finally, potential confounding variables such as lifestyle habits, occupational exposures, dietary patterns, and psychological stress were not controlled, all of which may impact OS levels and antioxidant status. Conclusion The present work underscores the importance of seminal OS, manifested by increased cfDNA and decreased TAC, on the pathophysiology of male infertility and ICSI outcome. Our findings reveal that sperm abnormalities are associated with significant oxidative imbalance, which in turn correlates with impaired sperm motility, morphology, and, importantly, poor ICSI outcomes such as reduced pregnancy rates and elevated miscarriage incidence. cfDNA and TAC could be valuable predictive markers for embryo quality, pregnancy success, and miscarriage risk. Taken together, these findings support the incorporation of cfDNA and TAC measurements into the practice of diagnostic fertility testing, thereby providing a more comprehensive and clinically relevant representation of male reproductive potential and facilitating a highly individualized treatment strategy in ART. Recommendations Based on the present work, several recommendations can be made to direct future research and clinical practice. Incorporating cfDNA and TAC assessments into routine semen analysis may enhance diagnostic accuracy, particularly in cases of unexplained male infertility. Men with high seminal cfDNA or low TAC might benefit from antioxidant therapy before ICSI. In order to increase the generalizability of the findings, multi-center studies with large sample size and diverse population are urgently needed to validate and establish cut-off values for cfDNA and TAC in ART program. Furthermore, integration of cfDNA and TAC levels with classic parameters of semen analysis and the advanced OS biomarkers such as DFI could be useful for a more comprehensive assessment of male fertility potential. Future studies should also aim to investigate cfDNA levels in frozen semen samples, and examine the relationship between seminal cfDNA and other OS biomarkers. Data availability Underlying data Figshare : Extended data for The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with Intracytoplasmic Sperm Injection Outcomes in Iraqi infertile men. https://doi.org/10.6084/m9.figshare.29485400.v1 92 This project contains the following underlying data: - Participant Clinical Questionnaire : Form used to collect demographic, medical, and reproductive data - Informed Consent Form : A form explaining the study and confirming voluntary participant consent - Study Materials : Kits, Chemicals, and Equipment - Research Data (Excel File): Raw and processed data from participants - Supplementary Tables : Additional statistical tables Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0 ). References 1. Agarwal A, Baskaran S, Parekh N, et al. : Male infertility. Lancet. 2021; Vol. 397 : pp. 319–333. Lancet Publishing Group. Publisher Full Text 2. Naz M, Kamal M: Classification, causes, diagnosis and treatment of male infertility: a review. Orient Pharm Exp Med. 2017; Vol. 17 : pp. 89–109. Springer Netherlands. Publisher Full Text 3. Oehninger S, Ombelet W: Limits of current male fertility testing. Fertil. Steril. 2019; Vol. 111 : pp. 835–841. Elsevier Inc. Publisher Full Text 4. Avendaño C, Oehninger S: DNA fragmentation in morphologically normal spermatozoa: How much should we be concerned in the ICSI era? J. Androl. 2011; 32 : 356–363. 5. Cho CL, Agarwal A: Role of sperm DNA fragmentation in male factor infertility: A systematic review. Arab. J. Urol. 2018 Mar 1; 16 (1): 21–34. PubMed Abstract | Publisher Full Text | Free Full Text 6. Agarwal A, Virk G, Ong C, et al. : Effect of Oxidative Stress on Male Reproduction. World J. Mens Health. 2014; 32 (1): 1–17. PubMed Abstract | Publisher Full Text | Free Full Text 7. Sinan F, Al-Qadhi HI, Al Kareem BA: N-acetyl cysteine’s effect on semen parameters in a sample of Iraqi men with oligoasthenoteratozoospermia. J. Fac. Med. Baghdad. 2022 Oct 17; 64 (3): 170–174. 8. Abdul Aziz AS, Elyaseen HD, Kadhem HK: Correlation between MDA Level and Chitotriosidase-1 Activity in Seminal Fluid of Iraqi Infertile Males. J. Fac. Med. Baghdad. 2024 Dec 31; 66 (4): 479–486. Publisher Full Text Reference Source 9. Alahmar A: Role of oxidative stress in male infertility: An updated review. J. Hum. Reprod. Sci. 2019; Vol. 12 : pp. 4–18. Wolters Kluwer Medknow Publications. PubMed Abstract | Publisher Full Text | Free Full Text 10. Wang Y, Fu X, Li H: Mechanisms of oxidative stress-induced sperm dysfunction. Front. Endocrinol. 2025: Vol. 16 . Frontiers Media SA. Publisher Full Text 11. Shareef BQ, Al Qadhi HI, Jamal SA: Antioxidant Effects of Selenium Nanoparticles Prepared from Eruca Sativa Extract on Ketoconazole –Induced Testicular Oxidative Damage in Male Rats. J. Fac. Med. Baghdad. 2024 Apr 1; 66 (1): 58–66. Publisher Full Text 12. Hasan HR: Evaluation of some individual antioxidants in seminal plasma of fertile & infertile men.2003. Reference Source 13. Saleh MMS, Al-Wasiti A, Muslim AN: Role of Caspase-3 and Total Antioxidant Capacity (TAC) in Idiopathic Infertile Male.2018. Publisher Full Text 14. Pahune PP, Choudhari AR, Muley PA: The total antioxidant power of semen and its correlation with the fertility potential of human male subjects. J. Clin. Diagn. Res. 2013; 7 (6): 991–995. PubMed Abstract | Publisher Full Text 15. de Miranda FS , Barauna VG, Dos Santos L, et al. : Properties and application of cell-free DNA as a clinical biomarker. Int. J. Mol. Sci. 2021; Vol. 22 . MDPI. PubMed Abstract | Publisher Full Text | Free Full Text 16. Grabuschnig S, Bronkhorst AJ, Holdenrieder S, et al. : Putative origins of cell-free DNA in humans: A review of active and passive nucleic acid release mechanisms. Int. J. Mol. Sci. 2020; Vol. 21 : pp. 1–24. MDPI AG. PubMed Abstract | Publisher Full Text | Free Full Text 17. Chou JS, Jacobson JD, Patton WC, et al. : Modified Isocratic Capillary Electrophoresis Detection of Cell-free DNA in Semen. J. Assist. Reprod. Genet. 2004; 21 : 397–400. PubMed Abstract | Publisher Full Text | Free Full Text 18. Qasemi M, Mahdian R, Amidi F: Cell-free DNA discoveries in human reproductive medicine: providing a new tool for biomarker and genetic assays in ART. J. Assist. Reprod. Genet. 2021; 38 : 277–288. PubMed Abstract | Publisher Full Text | Free Full Text 19. Li HG, Huang SY, Zhou H, et al. : Quick recovery and characterization of cell-free DNA in seminal plasma of normozoospermia and azoospermia: Implications for non-invasive genetic utilities. Asian J. Androl. 2009; 11 (6): 703–709. PubMed Abstract | Publisher Full Text | Free Full Text 20. Zhou Y, Wang J, Zhang F, et al. : DNA breakpoints and free DNA fragments as potential predictors of infertility. Sci. Rep. 2024 Dec 1; 14 (1): 29665. PubMed Abstract | Publisher Full Text | Free Full Text 21. Di Pizio P, Celton N, Menoud PA, et al. : Seminal cell-free DNA and sperm characteristic’s: An added biomarker for male infertility investigation. Andrologia. 2020 Feb 1; 53 (1). Publisher Full Text 22. Bungum M, Humaidan P, Axmon A, et al. : Sperm DNA integrity assessment in prediction of assisted reproduction technology outcome. Hum. Reprod. 2007; 22 (1): 174–179. 23. Sun TC, Zhang Y, Li HT, et al. : Sperm DNA fragmentation index, as measured by sperm chromatin dispersion, might not predict assisted reproductive outcome. Taiwan. J. Obstet. Gynecol. 2018 Aug 1; 57 (4): 493–498. Publisher Full Text 24. Al Omrani B, Al Eisa N, Javed M, et al. : Associations of sperm DNA fragmentation with lifestyle factors and semen parameters of Saudi men and its impact on ICSI outcome. Reprod. Biol. Endocrinol. 2018 May 19; 16 (1): 49. PubMed Abstract | Publisher Full Text | Free Full Text 25. Sharma R, Agarwal A, Rohra VK, et al. : Effects of increased paternal age on sperm quality, reproductive outcome and associated epigenetic risks to offspring. Reprod. Biol. Endocrinol. 2015; Vol. 13 : 35. BioMed Central Ltd. PubMed Abstract | Publisher Full Text | Free Full Text 26. Wu Y, Kang X, Zheng H, et al. : Effect of paternal age on reproductive outcomes of intracytoplasmic sperm injection. PLoS One. 2016 Feb 1; 11 (2). Publisher Full Text 27. Duran EH, Dowling-Lacey D, Bocca S, et al. : Impact of male age on the outcome of assisted reproductive technology cycles using donor oocytes. Reprod. Biomed. Online. 2010; 20 (6): 848–856. Publisher Full Text 28. Cito G, Coccia ME, Picone R, et al. : Impact of advanced paternal age on the intracytoplasmic sperm injection (ICSI) outcomes in donor egg cycles. Transl. Androl. Urol. 2019; 8 : S22–S30. PubMed Abstract | Publisher Full Text | Free Full Text 29. Luna M, Finkler E, Barritt J, et al. : Paternal age and assisted reproductive technology outcome in ovum recipients. Fertil. Steril. 2009 Nov; 92 (5): 1772–1775. PubMed Abstract | Publisher Full Text 30. Wu Y, Kang X, Zheng H, et al. : Effect of paternal age on reproductive outcomes of intracytoplasmic sperm injection. PLoS One. 2016 Feb 1; 11 (2). Publisher Full Text 31. Harlev A, Agarwal A, Gunes SO, et al. : Smoking and Male Infertility: An Evidence-Based Review. World J. Mens Health. 2015; 33 (3): 143–160. PubMed Abstract | Publisher Full Text | Free Full Text 32. Sharma R, Harlev A, Agarwal A, et al. : Cigarette Smoking and Semen Quality: A New Meta-analysis Examining the Effect of the 2010 World Health Organization Laboratory Methods for the Examination of Human Semen. Eur. Urol. 2016; Vol. 70 : pp. 635–645. Elsevier B.V. PubMed Abstract | Publisher Full Text 33. Harmoosh SK, Al Madfai ZA: The influence of smoking on male reproductive parameters in a group of Iraqi subfertile men. J. Fac. Med. Baghdad. 2012; 54 : 146–150. Publisher Full Text 34. Javidmehr D, Fesahat F, Hassani F, et al. : Seminal cell-free nucleic acids as possible biomarker in male infertility: a mini-review article. Afr. J. Urol. 2024; Vol. 30 . Springer Science and Business Media Deutschland GmbH. Publisher Full Text 35. Mbaye MM, Zekhnini H, El KB, et al. : Determination of Free DNA (cfDNA) by RT-qPCR in Individuals in Sperm Alterations. Annu. Res. Rev. Biol. 2021 May 4; 1–6. Publisher Full Text 36. Costa F, Barbisan F, Assmann CE, et al. : Seminal cell-free DNA levels measured by PicoGreen fluorochrome are associated with sperm fertility criteria. Zygote. 2017 Apr 1; 25 (2): 111–119. PubMed Abstract | Publisher Full Text 37. Aitken RJ, Whiting S, Connaughton H, et al. : A novel pathway for the induction of DNA damage in human spermatozoa involving extracellular cell-free DNA. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2020 May 1; 821 : 111722. Publisher Full Text 38. Evenson DP, Larson KL, Jost LK: Sperm chromatin structure assay: Its clinical use for detecting sperm DNA fragmentation in male infertility and comparisons with other techniques. J. Androl. 2002; Vol. 23 : pp. 25–43. American Society of Andrology Inc. PubMed Abstract | Publisher Full Text 39. Alani GT, El Yaseen HD: Creatine Kinase Activity and Malondialdehyde in the Seminal Plasma Creatine Kinase Activity and Malondialdehyde in the Seminal Plasma of Normospermic Infertile Males. Normospermic Infertile Males J. Fac. Med. Baghdad. 2009; 50 . 40. Oliva R: Protamines and male infertility. Hum. Reprod. Update. 2006; 12 : 417–435. Publisher Full Text 41. Sakkas D, Alvarez JG: Sperm DNA fragmentation: mechanisms of origin, impact on reproductive outcome, and analysis. Fertil. Steril. 2010 Mar 1; 93 (4): 1027–1036. PubMed Abstract | Publisher Full Text 42. Tremellen K: Oxidative stress and male infertility - A clinical perspective. Hum. Reprod. Update. 2008; 14 : 243–258. PubMed Abstract | Publisher Full Text 43. Pahune PP, Choudhari AR, Muley PA: The total antioxidant power of semen and its correlation with the fertility potential of human male subjects. J. Clin. Diagn. Res. 2013; 7 (6): 991–995. PubMed Abstract | Publisher Full Text 44. Giulini S, Sblendorio V, Xella S, et al. : Seminal plasma total antioxidant capacity and semen parameters in patients with varicocele. Reprod. Biomed. Online. 2009; 18 (5): 617–621. PubMed Abstract | Publisher Full Text 45. Demir M, Ozdem S: Evaluation of total antioxidant capacity in human seminal plasma. Int. J. Med. Biochem. 2022; 5 (1): 54–59. 46. Alahmar AT, Calogero AE, Sengupta P, et al. : Coenzyme Q10 improves sperm parameters, oxidative stress markers and sperm DNA fragmentation in infertile patients with idiopathic oligoasthenozoospermia. World J. Mens Health. 2021; 39 (2): 346–351. PubMed Abstract | Publisher Full Text | Free Full Text 47. Eroglu M, Sahin S, Durukan B, et al. : Blood serum and seminal plasma selenium, total antioxidant capacity and coenzyme Q10 levels in relation to semen parameters in men with idiopathic infertility. Biol. Trace Elem. Res. 2014; 159 (1–3): 46–51. PubMed Abstract | Publisher Full Text 48. Wagner H, Cheng JW, Ko EY: Role of reactive oxygen species in male infertility: An updated review of literature. Arab. J. Urol. 2018 Mar 1; 16 (1): 35–43. PubMed Abstract | Publisher Full Text | Free Full Text 49. Khosrowbeygi A, Zarghami N: SEMINAL PLASMA LEVELS OF FREE 8-ISOPROSTANE AND ITS RELATIONSHIP WITH SPERM QUALITY PARAMETERS. Indian J. Clin. Biochem. 2008; 23 : 49–52. PubMed Abstract | Publisher Full Text | Free Full Text 50. Javidmehr D, Fesahat F, Hassani F, et al. : Differential significance of Seminal Cell-Free DNA Levels, Oxidative Stress, and Sperm Characteristic between Infertile Men with Nonobstructive and obstructive Azoospermia. JBRA Assist. Reprod. 2025; 1–7. PubMed Abstract | Publisher Full Text Reference Source 51. Agarwal A, Majzoub A, Baskaran S, et al. : Sperm DNA fragmentation: A new guideline for clinicians. World Journal of Men’s Health. 2020; Vol. 38 : 412. Korean Society for Sexual Medicine and Andrology. Publisher Full Text 52. Aitken RJ, De Iuliis GN: Origins and consequences of DNA damage in male germ cells. Reprod. Biomed. Online. 2007; Vol. 14 . pp. 727–733. Reproductive Healthcare Ltd. PubMed Abstract | Publisher Full Text 53. Henkel R, Kierspel E, Hajimohammad M, et al. : DNA fragmentation of spermatozoa and assisted reproduction technology. Reprod. Biomed. Online. 2003; 7 (4): 477–484. Publisher Full Text 54. Li F, Duan X, Li M, et al. : Sperm DNA fragmentation index affect pregnancy outcomes and offspring safety in assisted reproductive technology. Sci. Rep. 2024 Dec 1; 14 (1). Publisher Full Text 55. Sivanarayana T, Ravi Krishna C, Jaya Prakash G, et al. : Sperm DNA fragmentation assay by sperm chromatin dispersion (SCD): Correlation between DNA fragmentation and outcome of intracytoplasmic sperm injection. Reprod. Med. Biol. 2014; 13 (2): 87–94. PubMed Abstract | Publisher Full Text | Free Full Text 56. Lopes S, Sun JG, Jurisicova A, et al. : Sperm deoxyribonucleic acid fragmentation is increased in poor-quality semen samples and correlates with failed fertilization in intracytoplasmic sperm injection.1998. 57. Huang CC, Lin DPC, Tsao HM, et al. : Sperm DNA fragmentation negatively correlates with velocity and fertilization rates but might not affect pregnancy rates. Fertil. Steril. 2005; 84 (1): 130–140. PubMed Abstract | Publisher Full Text 58. Virro MR, Larson-Cook KL, Evenson DP: Sperm chromatin structure assay (SCSA) parameters are related to fertilization, blastocyst development, and ongoing pregnancy in in vitro fertilization and intracytoplasmic sperm injection cycles. Fertil. Steril. 2004; 81 (5): 1289–1295. PubMed Abstract | Publisher Full Text 59. Ribas-Maynou J, Novo S, Torres M, et al. : Sperm DNA integrity does play a crucial role for embryo development after ICSI, notably when good-quality oocytes from young donors are used. Biol. Res. 2022 Dec 1; 55 (1): 41. PubMed Abstract | Publisher Full Text | Free Full Text 60. Avendaño C, Franchi A, Taylor S, et al. : Fragmentation of DNA in morphologically normal human spermatozoa. Fertil. Steril. 2009 Apr; 91 (4): 1077–1084. Publisher Full Text 61. Simon L, Castillo J, Oliva R, et al. : Relationships between human sperm protamines, DNA damage and assisted reproduction outcomes. Reprod. Biomed. Online. 2011 Dec; 23 (6): 724–734. PubMed Abstract | Publisher Full Text 62. Seli E, Gardner DK, Schoolcraft WB, et al. : Extent of nuclear DNA damage in ejaculated spermatozoa impacts on blastocyst development after in vitro fertilization. Fertil. Steril. 2004; 82 (2): 378–383. PubMed Abstract | Publisher Full Text 63. Borini A, Tarozzi N, Bizzaro D, et al. : Sperm DNA fragmentation: Paternal effect on early post-implantation embryo development in ART. Hum. Reprod. 2006; 21 (11): 2876–2881. PubMed Abstract | Publisher Full Text 64. Robinson L, Gallos ID, Conner SJ, et al. : The effect of sperm DNA fragmentation on miscarriage rates: A systematic review and meta-analysis. Hum. Reprod. 2012; Vol. 27 : pp. 2908–2917. Oxford University Press. PubMed Abstract | Publisher Full Text 65. Siddhartha N, Reddy NS, Pandurangi M, et al. : The effect of sperm DNA fragmentation index on the outcome of intrauterine insemination and intracytoplasmic sperm injection. J. Hum. Reprod. Sci. 2019 Jul 1; 12 (3): 189–198. PubMed Abstract | Publisher Full Text | Free Full Text 66. Simon L, Zini A, Dyachenko A, et al. : A systematic review and meta-analysis to determine the effect of sperm DNA damage on in vitro fertilization and intracytoplasmic sperm injection outcome. Asian J. Androl. 2017; Vol. 19 : pp. 80–90. Medknow Publications. PubMed Abstract | Publisher Full Text 67. Jiang H, He RB, Wang CL, et al. : The relationship of sperm DNA fragmentation index with the outcomes of in-vitro fertilisation-embryo transfer and intracytoplasmic sperm injection. J. Obstet. Gynaecol. (Lahore). 2011 Oct; 31 (7): 636–639. PubMed Abstract | Publisher Full Text 68. Benchaib M, Braun V, Lornage J, et al. : Sperm DNA fragentation decreases the pregnancy rate in an assisted reproductive technique. Hum. Reprod. 2003 May 1; 18 (5): 1023–1028. PubMed Abstract | Publisher Full Text 69. Larson-Cook KL, Brannian JD, Hansen KA, et al. : Relationship between the outcomes of assisted reproductive techniques and sperm DNA fragmentation as measured by the sperm chromatin structure assay MALE FACTOR. Fertil. Steril. 2003; 80 (4): 895–902. PubMed Abstract | Publisher Full Text 70. Zini A, Boman JM, Belzile E, et al. : Sperm DNA damage is associated with an increased risk of pregnancy loss after IVF and ICSI: Systematic review and meta-analysis. Hum. Reprod. 2008; Vol. 23 : pp. 2663–2668. Oxford University Press. PubMed Abstract | Publisher Full Text 71. Boe-Hansen GB, Fedder J, Ersbøll AK, et al. : The sperm chromatin structure assay as a diagnostic tool in the human fertility clinic. Hum. Reprod. 2006; 21 (6): 1576–1582. PubMed Abstract | Publisher Full Text 72. Lin MH, Kuo-Kuang Lee R, Li SH, et al. : Sperm chromatin structure assay parameters are not related to fertilization rates, embryo quality, and pregnancy rates in in vitro fertilization and intracytoplasmic sperm injection, but might be related to spontaneous abortion rates. Fertil. Steril. 2008 Aug; 90 (2): 352–359. Publisher Full Text 73. Zhao J, Zhang Q, Wang Y, et al. : Whether sperm deoxyribonucleic acid fragmentation has an effect on pregnancy and miscarriage after in vitro fertilization/intracytoplasmic sperm injection: A systematic review and meta-analysis. Fertil. Steril. 2014 Oct 1; 102 (4): 998–1005.e8. PubMed Abstract | Publisher Full Text 74. Braude P, Bolton V, Moore S: Human gene expression first occurs between the four- and eight-cell stages of preimplantation development. Nature. 1988; 332 : 459–461. PubMed Abstract | Publisher Full Text 75. Greco E, Iacobelli M, Rienzi L, et al. : Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. J. Androl. 2005 May; 26 (3): 349–353. PubMed Abstract | Publisher Full Text 76. Scaruffi P, Licata E, Maccarini E, et al. : Oral antioxidant treatment of men significantly improves the reproductive outcome of IVF cycles. J. Clin. Med. 2021 Aug 1; 10 (15). PubMed Abstract | Publisher Full Text | Free Full Text 77. Gupta S, Finelli R, Agarwal A, et al. : Total antioxidant capacity—Relevance, methods and clinical implications. Andrologia. 2020; Vol. 53 . Blackwell Publishing Ltd. 78. Alahmar AT: The effects of oral antioxidants on the semen of men with idiopathic oligoasthenoteratozoospermia. Clin. Exp. Reprod. Med. 2018; Vol. 45 : pp. 57–66. Korean Society for Reproductive Medicine. PubMed Abstract | Publisher Full Text | Free Full Text 79. Appasamy M, Muttukrishna S, Pizzey AR, et al. : Relationship between male reproductive hormones, sperm DNA damage and markers of oxidative stress in infertility. Reprod. Biomed. Online. 2007; 14 (2): 159–165. PubMed Abstract | Publisher Full Text 80. Le MT, Nguyen TAT, Nguyen HTT, et al. : Does sperm DNA fragmentation correlate with semen parameters? Reprod. Med. Biol. 2019 Oct 1; 18 (4): 390–396. PubMed Abstract | Publisher Full Text | Free Full Text 81. Liu KS, Mao XD, Pan F, et al. : Correlation analysis of sperm DNA fragmentation index with semen parameters and the effect of sperm DFI on outcomes of ART. Sci. Rep. 2023 Dec 1; 13 (1). Publisher Full Text 82. Shi X, Chan CPS, Waters T, et al. : Lifestyle and demographic factors associated with human semen quality and sperm function. Syst. Biol. Reprod. Med. 2018 Sep 3; 64 (5): 358–367. PubMed Abstract | Publisher Full Text 83. Das M, Al-Hathal N, San-Gabriel M, et al. : High prevalence of isolated sperm DNA damage in infertile men with advanced paternal age. J. Assist. Reprod. Genet. 2013 Jun; 30 (6): 843–848. PubMed Abstract | Publisher Full Text | Free Full Text 84. Rybar R, Kopecka V, Prinosilova P, et al. : Male obesity and age in relationship to semen parameters and sperm chromatin integrity. Andrologia. 2011 Aug; 43 (4): 286–291. PubMed Abstract | Publisher Full Text 85. Chua SC, Yovich SJ, Hinchliffe PM, et al. : Male Clinical Parameters (Age, Stature, Weight, Body Mass Index, Smoking History, Alcohol Consumption) Bear Minimal Relationship to the Level of Sperm DNA Fragmentation. J. Pers. Med. 2023 May 1; 13 (5). PubMed Abstract | Publisher Full Text | Free Full Text 86. Kort HI, Massey JB, Elsner CW, et al. : Impact of body mass index values on sperm quantity and quality. J. Androl. 2006 May; 27 (3): 450–452. PubMed Abstract | Publisher Full Text 87. La Vignera S , Condorelli RA, Vicari E, et al. : Negative effect of increased body weight on sperm conventional and nonconventional flow cytometric sperm parameters. J. Androl. 2012 Jan; 33 (1): 53–58. PubMed Abstract | Publisher Full Text 88. Fariello RM, Pariz JR, Spaine DM, et al. : Association between obesity and alteration of sperm DNA integrity and mitochondrial activity. BJU Int. 2012 Sep; 110 (6): 863–867. PubMed Abstract | Publisher Full Text 89. Khosrowbeygi A, Zarghami N: Levels of oxidative stress biomarkers in seminal plasma and their relationship with seminal parameters. BMC Clin. Pathol. 2007; 7 . PubMed Abstract | Publisher Full Text | Free Full Text 90. Koca Y, Özdal ÖL, Çelik M, et al. : Antioxidant activity of seminal plasma in fertile and infertile men. Arch. Androl. 2003; 49 (5): 355–359. Publisher Full Text 91. Ammar OA, El-Gazzar MA, El-Nashar ABM, et al. : The Relationship between Seminal Total Antioxidant Capacity and Idiopathic Repeated Pregnancy Loss. Egypt J. Fertil. Steril. 2023; 27 (3): 77–85. Publisher Full Text 92. Alshammary H: Extended data for The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with Intracytoplasmic Sperm Injection Outcomes in Iraqi infertile men. Dataset. figshare 2025. Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 22 Jul 2025 ADD YOUR COMMENT Comment Author details Author details 1 Department of Physiology, University of Baghdad, College of Medicine, Baghdad, 10011, Iraq Hadeer S. Al- Shammary Roles: Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Software, Writing – Original Draft Preparation Hanan L. Al-Omary Roles: Conceptualization, Methodology, Supervision, Validation, Visualization, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (1) version 1 Published: 22 Jul 2025, 14:719 https://doi.org/10.12688/f1000research.166880.1 Copyright © 2025 S. Al- Shammary H and L. Al-Omary H. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article S. Al- Shammary H and L. Al-Omary H. The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with Intracytoplasmic Sperm Injection Outcomes in Iraqi Infertile men [version 1; peer review: 1 approved] . F1000Research 2025, 14 :719 ( https://doi.org/10.12688/f1000research.166880.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 1 VERSION 1 PUBLISHED 22 Jul 2025 Views 0 Cite How to cite this report: Maulida S. Reviewer Report For: The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with Intracytoplasmic Sperm Injection Outcomes in Iraqi Infertile men [version 1; peer review: 1 approved] . F1000Research 2025, 14 :719 ( https://doi.org/10.5256/f1000research.183931.r405791 ) The direct URL for this report is: https://f1000research.com/articles/14-719/v1#referee-response-405791 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 29 Aug 2025 Siti Maulida , Universitas Syiah Kuala, Banda Aceh, Indonesia Approved VIEWS 0 https://doi.org/10.5256/f1000research.183931.r405791 This study included 65 ICSI couples to evaluate the association between seminal cell-free DNA (cfDNA) measured by qPCR and total antioxidant capacity (TAC) measured by FRAP assay with embryo quality, fertilization, pregnancy, and miscarriage outcomes. Results show higher cfDNA and ... Continue reading READ ALL This study included 65 ICSI couples to evaluate the association between seminal cell-free DNA (cfDNA) measured by qPCR and total antioxidant capacity (TAC) measured by FRAP assay with embryo quality, fertilization, pregnancy, and miscarriage outcomes. Results show higher cfDNA and lower TAC are linked to poorer ICSI outcomes. Underlying data are available on Figshare. This article addresses a clinically relevant topic in the field of male infertility, the methods are reasonably described and data are openly shared and the findings are biologically plausible and align with oxidative stress literature. Key Revisions Required Study Design & Outcomes Clarify whether the study is cross-sectional or prospective. Provide clear definitions of clinical pregnancy, miscarriage, and specify the embryo grading system. Method Validation Standardize TAC units (μmol/L Trolox equivalents). Detail pre-analytical handling (storage, freeze-thaw cycles, contamination control). Data & Reproducibility Ensure dataset includes all relevant variables (male/female age, smoking status, semen parameters, outcomes). Presentation Verify questionable value in Table 4 (cfDNA Grade I, normospermic group). (In Table 4, normospermic Grade I cfDNA = 0.053 ± 0.048 μg/mL appears an order of magnitude lower than Grades II–III (0.58–0.68). Confirm whether 0.053 is correct (not 0.53)). Standardize reporting of p-values and units. Conclusion This article is timely and relevant, with open data and plausible associations between seminal cfDNA/TAC and ICSI outcomes. However, it requires clearer outcome definitions and methodological validation. Addressing these points will enhance scientific validity and reproducibility. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes References 1. Javidmehr, D., Fesahat, F., Hassani, F. et al. Seminal cell-free nucleic acids as possible biomarker in male infertility: a mini-review article. Afr J Urol 30, 54 (2024). https://doi.org/10.1186/s12301-024-00450-1. Competing Interests: No competing interests were disclosed. Reviewer Expertise: Biology, Biotechnology, Cryopreservation I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Maulida S. Reviewer Report For: The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with Intracytoplasmic Sperm Injection Outcomes in Iraqi Infertile men [version 1; peer review: 1 approved] . F1000Research 2025, 14 :719 ( https://doi.org/10.5256/f1000research.183931.r405791 ) The direct URL for this report is: https://f1000research.com/articles/14-719/v1#referee-response-405791 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 22 Jul 2025 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 Version 1 22 Jul 25 read Siti Maulida , Universitas Syiah Kuala, Banda Aceh, Indonesia Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Maulida S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 29 Aug 2025 | for Version 1 Siti Maulida , Universitas Syiah Kuala, Banda Aceh, Indonesia 0 Views copyright © 2025 Maulida S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This study included 65 ICSI couples to evaluate the association between seminal cell-free DNA (cfDNA) measured by qPCR and total antioxidant capacity (TAC) measured by FRAP assay with embryo quality, fertilization, pregnancy, and miscarriage outcomes. Results show higher cfDNA and lower TAC are linked to poorer ICSI outcomes. Underlying data are available on Figshare. This article addresses a clinically relevant topic in the field of male infertility, the methods are reasonably described and data are openly shared and the findings are biologically plausible and align with oxidative stress literature. Key Revisions Required Study Design & Outcomes Clarify whether the study is cross-sectional or prospective. Provide clear definitions of clinical pregnancy, miscarriage, and specify the embryo grading system. Method Validation Standardize TAC units (μmol/L Trolox equivalents). Detail pre-analytical handling (storage, freeze-thaw cycles, contamination control). Data & Reproducibility Ensure dataset includes all relevant variables (male/female age, smoking status, semen parameters, outcomes). Presentation Verify questionable value in Table 4 (cfDNA Grade I, normospermic group). (In Table 4, normospermic Grade I cfDNA = 0.053 ± 0.048 μg/mL appears an order of magnitude lower than Grades II–III (0.58–0.68). Confirm whether 0.053 is correct (not 0.53)). Standardize reporting of p-values and units. Conclusion This article is timely and relevant, with open data and plausible associations between seminal cfDNA/TAC and ICSI outcomes. However, it requires clearer outcome definitions and methodological validation. Addressing these points will enhance scientific validity and reproducibility. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Yes Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes References 1. Javidmehr, D., Fesahat, F., Hassani, F. et al. Seminal cell-free nucleic acids as possible biomarker in male infertility: a mini-review article. Afr J Urol 30, 54 (2024). https://doi.org/10.1186/s12301-024-00450-1. Competing Interests No competing interests were disclosed. Reviewer Expertise Biology, Biotechnology, Cryopreservation I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Maulida S. Peer Review Report For: The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity with Intracytoplasmic Sperm Injection Outcomes in Iraqi Infertile men [version 1; peer review: 1 approved] . F1000Research 2025, 14 :719 ( https://doi.org/10.5256/f1000research.183931.r405791) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/14-719/v1#referee-response-405791 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "The Relation of Seminal Cell-Free DNA and...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/14-719/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/14-719/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/14-719/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('S. Al- Shammary H and L. Al-Omary H'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/14-719/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/14-719", templates : { twitter : "The Relation of Seminal Cell-Free DNA and Total Antioxidant Capacity.... S. Al- Shammary H and L. Al-Omary H, published by " + "@F1000Research" + ", https://f1000research.com/articles/14-719/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/166880/183931") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "183931"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "403095": 0, "403093": 0, "405790": 0, "405791": 7, "403100": 0, "405788": 0, "405789": 0, "403098": 0, "405786": 0, "403099": 0, "405787": 0, "403096": 0, "403097": 0, "405785": 0, "403108": 0, "403106": 0, "405794": 0, "403107": 0, "405792": 0, "405793": 0, "411438": 0, "411439": 0, "411436": 0, "411437": 0, "411444": 0, "411445": 0, "411442": 0, "411443": 0, "411440": 0, "411441": 0, "418622": 0, "418623": 0, "415039": 0, "418620": 0, "418621": 0, "418619": 0, "415046": 0, "415047": 0, "418628": 0, "415044": 0, "418629": 0, "415045": 0, "418626": 0, "415042": 0, "418627": 0, "415043": 0, "418624": 0, "415040": 0, "418625": 0, "415041": 0, "415048": 0, "408926": 0, "408927": 0, "408934": 0, "408935": 0, "408932": 0, "408933": 0, "408930": 0, "408931": 0, "408928": 0, "408929": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "6eb0145f-7b9c-4922-ab96-35827286b7d0"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });